环氧合酶2抑制剂对非酒精性脂肪性肝病大鼠模型回肠Acsl基因家族表达的影响

郭珊; 易世杰; 阳学风; 曹婷; 傅念; 周克兵; 龙建武

doi:10.3969/j.issn.1001-5256.2020.09.026

环氧合酶2抑制剂对非酒精性脂肪性肝病大鼠模型回肠Acsl基因家族表达的影响

DOI: 10.3969/j.issn.1001-5256.2020.09.026

南华大学附属南华医院消化内科

基金项目:

国家自然科学基金(81373465)；湖南省自然科学省市联合基金(2016JJ5010)；湖南省卫生计生委科研课题(A2017015)；湖南省卫生健康委科研立项课题(20201938)；衡阳市科技局课题(181)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1172
- HTML全文浏览量: 51
- PDF下载量: 93
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Effect of cyclooxygenase-2 inhibitors on the expression of the Acsl gene family in the ileum of rats with nonalcoholic fatty liver disease

Department of Gastroenterology, Nanhua Hospital Affiliated to Nanhua University

Research funding:

摘要

摘要:
目的研究环氧合酶2（COX-2）抑制剂对非酒精性脂肪性肝病（NAFLD）大鼠模型回肠Acsl基因家族表达的影响及意义。方法将45只SD大鼠随机分为3组:正常对照组（n=15只,普通饲料）、NAFLD模型组（n=15,高脂饲料）、尼美舒利组（n=15,高脂饲料+尼美舒利）。所有SD大鼠喂养到第12周处死。采集下腔静脉血,检测其总胆固醇（TC）、甘油三酯（TG）。肝组织行HE染色和油红O染色,评价各组大鼠肝组织脂肪变性程度。实时荧光定量PCR法检测回肠Acsl家族各基因的表达情况。计量资料多组间比较采用方差分析,进一步两两比较采用LSD-t检验。结果与正常对照组大鼠比较,NAFLD模型组血清TC、TG值均明显增加,肝脏脂肪变性明显（P值均<0.05）;尼美舒利组与NAFLD模型组比较,血清TC、TG值均明显下降,肝脏脂肪变性程度减轻（P值均<0.05）;与正常对照组大鼠相比,NAFLD模型组大鼠回肠COX-2的表达明显升高（P <0.05）;与NAFLD模型组大鼠相比,尼美舒利组回肠COX-2的表达明显降低（P <0.05）;与正常对照组相比,NAFLD模型组回肠A...
- 环氧化酶2 /
- 非酒精性脂肪性肝病 /
- 大鼠,Sprague-Dawley /
- 基因
Abstract:
Objective To investigate the effect and significance of cyclooxygenase-2( COX-2) inhibitors on the expression of the Acsl gene family in the ileum of rats with nonalcoholic fatty liver disease( NAFLD). Methods A total of 45 Sprague-Dawley rats were randomly divided into normal control group( 15 rats given normal diet),NAFLD model group( 15 rats given high-fat diet),and nimesulide group( 15 rats given high-fat diet and nimesulide). All rats were sacrificed after 12 weeks of feeding,and then blood samples were collected from the inferior vena cava to measure total cholesterol( TC) and triglyceride( TG). HE staining and oil red O staining were performed for the liver to evaluate the degree of hepatic steatosis in each group,and quantitative real-time PCR was used to measure the mRNA expression of the Acsl family genes in the ileum. An analysis of variance was used for comparison of continuous data between multiple groups,and the least significant difference t-test was used for further comparison between two groups. Results Compared with the normal control group,the NAFLD model group had significant increases in serum TC and TG and marked hepatic steatosis( all P < 0. 05); compared with the NAFLD model group,the nimesulide group had significant reductions in serum TC and TG and degree of hepatic steatosis( all P < 0. 05). Compared with the normal control group,the NAFLD model group had a significant increase in the expression of COX-2 in the ileum( P < 0. 05),and compared with the NAFLD model group,the nimesulide group had a significant reduction in the expression of COX-2 in the ileum( P <0. 05). Compared with the normal control group,the NAFLD model group had significant increases in the mRNA expression of Acsl3 and Acsl5 in the ileum( both P < 0. 05),and compared with the NAFLD model group,the nimesulide group had significant reductions in the mRNA expression of Acsl3 and Acsl5( both P < 0. 05). Conclusion The COX-2 inhibitor nimesulide can regulate the expression of the Acsl gene family in the ileum of rats with NAFLD,suggesting that COX-2 inhibitors may inhibit the progression of NAFLD through the Acsl gene.
- cyclooxygenase 2 /
- non-alcoholic fatty liver disease /
- rats,sprague-dawley /
- genes

HTML全文

参考文献(30)

[1] YOUNOSSI ZM. Non-alcoholic fatty liver disease-A global public health perspective[J]. J Hepatol,2019,70(3):531-544.

[2] CAO MB,DONG L,LU XL,et al. Expression of cyclooxygenase-2 in nonalcoholic fatty liver disease and its significance[J]. J Fourth Milit Med Univ,2008,29(14):1282-1285.(in Chinese)曹名波，董蕾，鲁晓岚，等．环氧合酶-2在非酒精性脂肪肝病中的表达及意义[J]．第四军医大学学报，2008,29(14):1282-1285.

[3] CUSI K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis[J]. Clin Liver Dis,2009,13(4):545-563.

[4] FOURET G,GAILLET S,LECOMTE J,et al. 20-Week fol owup of hepatic steatosis installation and liver mitochondrial structure and activity and their interrelation in rats fed a high-fat-highfructose diet[J]. Br J Nutr,2018,119(4):368-380.

[5] LIU Z,HUANG Y,ZHANG Y,et al. Drosophila Acyl-Co A synthetase long-chain family member 4 regulates axonal transport of synaptic vesicles and is required for synaptic development and transmission[J]. Neurosci,2011,31(6):2052-2063.

[6] KRAWCZYK M,BONFRATE L,PORTINCASA P,et al. Nonalcoholic fatty liver disease[J]. Best Pract Res Clin Gastroenterol,2010,24(5):695-708.

[7] VELAGAPUDI VR,HEZAVEH R,REIGSTAD CS,et al. The gut microbiota modulates host energy and lipid metabolism in mice[J]. J Lipid Res,2010,51(5):1101-1112.

[8] JING XY,YANG XF. The effect of COX-2 on expression of Acsl family related genes in HSC-T6 cells[D]. Hengyang:The University of South China,2014.(in Chinese)靖新艳，阳学风．COX-2对HSC-T6细胞中Acsl家族相关基因表达的影响[D]．衡阳:南华大学，2014.

[9] BAFFY G. Potential mechanisms linking gut microbiota and portal hypertension[J]. Liver Int,2019,39(4):598-609.

[10] LAU E,CARVALHO D,FREITAS P. Gut microbiota:Association with NAFLD and metabolic disturbances[J]. Biomed Res Int,2015,2015:979515.

[11] SUO YH,LIU JC. Research advances in the treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol,2018,34(10):2232-2236.(in Chinese)索宇鸿，刘近春．非酒精性脂肪性肝病的治疗进展[J]．临床肝胆病杂志，2018,34(10):2232-2236.

[12] COHEN JC,HORTON JD,HOBBS HH. Human fatty liver disease:Old questions and new insights[J]. Science,2011,332(6037):1519-1523.

[13] ISMAIL SA,SH ES,ZIADA DH,et al. Cytokeratin-18 in diagnosis of HCC in patients with liver cirrhosis[J]. Asian Pac J Cancer Prev,2017,18(4):1105-1111.

[14] BYRNE CD,TARGHER G. NAFLD:A multisystem disease[J]. J Hepatol,2015,62(1 Suppl):s47-s64.

[15] LI WY,YUAN CM. Research advances in integrated traditional Chinese and Western medicine therapy for nonalcoholic fatty liver disease[J]. J Clin Hepatol,2020,36(4):919-923.(in Chinese)李文怡，袁成民．非酒精性脂肪性肝病的中西医治疗[J]．临床肝胆病杂志，2020,36(4):919-923.

[16] TAKAKI A,KAWAI D,YAMAMOTO K. Multiple hits,including oxidative stress,as pathogenesis and treatment target in non-alcoholic steatohepatitis(NASH)[J]. Int J Mol Sci,2013,14(10):20704-20728.

[17] JASIRWAN C,LESMANA C,HASAN I,et al. The role of gut microbiota in non-alcoholic fatty liver disease:Pathways of mechanisms[J]. Biosci Microbiota Food Health,2019,38(3):81-88.

[18] VEENA J,MURAGUNDLA A,SIDGIDDI S,et al. Non-alcoholic fatty liver disease:Need for a balanced nutritional source[J]. Br J Nutr,2014,112(11):1858-1872.

[19] MOURIES J,BRESCIA P,SILVESTRI A,et al. Microbiotadriven gut vascular barrier disruption is a prerequisite for nonalcoholic steatohepatitis development[J]. J Hepatol,2019,71(6):1216-1228.

[20] SCHNEIDER KM,BIEGHS V,HEYMANN F,et al. CX3CR1 is a gatekeeper for intestinal barrier integrity in mice:Limiting steatohepatitis by maintaining intestinal homeostasis[J]. Hepatology,2015,62(5):1405-1416.

[21] PETITO-DA-SILVA TI,SOUZA-MELLO V,BARBOSA-DASILVA S. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance,lipogenesis and ER stress[J]. Mol Cel Endocrinol,2019,498:110539.

[22] HU J,HONG W,YAO KN,et al. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/m TOR/SREBP-1 signaling pathway[J]. World J Gastroenterol,2019,25(12):1492-1501.

[23] ZHANG C,Mc FARLANE C,LOKIREDDY S,et al. Inhibition of myostatin protects against diet-induced obesityby enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice[J]. Diabetologia,2012,55(1):183-193.

[24] TAI FWD. NSAIDs and the small bowel[J]. Current opinion in gastroenterology,2018,12(2):431-455.

[25] TTHˇS,JONECOVZ,C`URGALI K,et al. Quercetin attenuates the ischemia reperfusion induced COX-2 and MPO expression in the small intestine mucosa[J]. Biomed Pharmacother,2017,95:346-354.

[26] NEESS D,BEK S,ENGELSBY H,et al. Long-chain acylCo A esters in metabolism and signaling:Role of acyl-Co A binding proteins[J]. Prog Lipid Res,2015,59:1-25.

[27] POPPELREUTHER M,RUDOLPH B,DU C,et al. The N-terminal region of acyl-Co A synthetase 3 is essential for both the localization on lipid droplets and the function in fatty acid uptake[J]. J Lipid Res,2012,53(5):888-900.

[28] BAUER PV,DUCA FA,WAISE T,et al. Lactobacillus gasseri in the upper small intestine impacts an ACSL3-dependent fatty acid-sensing pathway regulating whole-body glucose homeostasis[J]. Cell Metab,2018,27(3):572-587. e6.

[29] REINARTZ A,EHLING J,LEUE A,et al. Lipid-induced upregulation of human acyl-Co A synthetase 5 promotes hepatocellular apoptosis[J]. Biochim Biophys Acta,2010,1801(9):1025-1035.

[30] TSUJIMOTO S,KISHINA M,KODA M,et al. Nimesulide,a cyclooxygenase-2 selective inhibitor,suppresses obesityrelated non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptorγ[J]. Int J Mol Med,2016,38(3):721-728.

施引文献

资源附件(0)

访问统计